Effectiveness and Tolerability of Zavegepant for Acute Migraine Treatment Among Those Using CGRP Targeting Preventive Medications

Inclusion criteria

• Meets International Classification of Headache Disorders 3 (ICHD-3) diagnostic criteria for migraine with or without aura
• At least 18 years of age
• 2- 8 migraine attacks per month
• Participants should be on a calcitonin gene-related peptide (CGRP)-targeting preventive migraine medication on a stable dose for a) ≥2 months prior to zavegepant treatment if an oral gepant or a monoclonal antibody (mAb) injected monthly, or b) at least two treatments if a mAb injected each 3 months.
• Atogepant
• Eptinezumab
• Erenumab
• Fremanezumab
• Galcanezumab
• Rimegepant

Exclusion criteria

• Primary headache disorders other than migraine (tension-type headache days are allowed)
• History of hypersensitivity reaction to zavegepant or to any of the components of zavegepant
• Eligibility Notes
• Participants may have either episodic or chronic migraine.
• Prior use of zavegepant and other gepants is permitted.
• Participants can be using migraine preventive medications/treatments in addition to the CGRP-targeting preventive treatment, as long as those treatments have been stable for at least two months at the time of enrollment.
• Additional Eligibility Criteria for Participants to Start on Rimegepant for Migraine Prevention
• Inclusion Criteria:
• Must have 4 or more migraine days per month, on average, during the 2 months prior to the Screening Visit, according to participant self-report.
• Exclusion Criteria
• History of hypersensitivity reaction to rimegepant or to any of the components of rimegepant.